In the next installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD, emphasizes a patient- and caregiver-centered approach to treatment planning—highlighting how clinical decisions...
Monitoring treatment response in myelofibrosis requires a balanced assessment of patient-reported symptoms, objective scoring tools, hematologic parameters, and spleen size. In part 1 of this Myelofibrosis...
In the final installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD interviews Tim F., a caregiver from Pittsburgh, PA, about the critical role caregivers play in shared...
In the latest installment of the Myelofibrosis Caregiver Interview Series, Tim F. from Pittsburgh, PA, talks with Fadi Haddad, MD about the caregiver perspective, highlighting the substantial day-to-day...
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
In this podcast episode, Dr Harrison discusses several case presentations of patients with abnormal laboratory values, including the evaluation of liver function test results, urinalysis results, and...
Blood eosinophil count is becoming increasingly recognized by the respiratory specialist community as a clinically relevant biomarker to help estimate affective management strategies, but the use is still...
In this episode, Amit Correa, MD, discusses the clinical evaluation and management of patients with an oral ulcer, including the causes, management of a patient with an aphthous ulcer, malignant and...
